Results 1 to 10 of about 7,778 (203)

Characterization of G6PD genotypes and phenotypes on the northwestern Thailand-Myanmar border.

open access: yesPLoS ONE, 2014
Mutations in the glucose-6-phosphate dehydrogenase (G6PD) gene result in red blood cells with increased susceptibility to oxidative damage. Significant haemolysis can be caused by primaquine and other 8-aminoquinoline antimalarials used for the radical ...
Germana Bancone   +7 more
doaj   +5 more sources

Genotypic and phenotypic characterization of G6PD deficiency in Bengali adults with severe and uncomplicated malaria [PDF]

open access: yesMalaria Journal, 2017
Background Control of malaria increasingly involves administration of 8-aminoquinolines, with accompanying risk of haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Katherine Plewes   +14 more
doaj   +3 more sources

Seasonal childhood anaemia in West Africa is associated with the haptoglobin 2-2 genotype.

open access: yesPLoS Medicine, 2006
BackgroundAnaemia is a major cause of morbidity and mortality for children in Africa. The plasma protein haptoglobin (Hp) binds avidly to free haemoglobin released following malaria-induced haemolysis.
Sarah H Atkinson   +8 more
doaj   +1 more source

Improving microbiological food Safety in peri-urban Mali; an experimental study

open access: yes, 2011
Introduction: Twenty years ago, a WHO review of the literature assumed that most food-borne disease transmission in developing countries takes place within the home, and advocated a major programme of interdisciplinary research to develop and test cost ...
Arby, Aminata   +4 more
core   +1 more source

Deficiência de glicose-6-fosfato desidrogenase eritrocitária em recém-nascidos do sexo masculino e sua relação com a icterícia neonatal [PDF]

open access: yes, 2010
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, the commonest red cell enzymopathy in humans, has an X-linked inheritance. The major clinical manifestations are drug induced hemolytic anemia, neonatal jaundice and chronic nonspherocytic hemolytic ...
AMORIM, Maria do Socorro T.   +6 more
core   +1 more source

Glucose-6-Phosphate Dehydrogenase Deficiency, Chlorproguanil-Dapsone with Artesunate and Post-treatment Haemolysis in African children treated for uncomplicated Malaria [PDF]

open access: yes, 2012
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA)
A Alloueche   +45 more
core   +3 more sources

Allelic variants of KLK2 gene predict presence of prostate cancer at biopsy [PDF]

open access: yes, 2016
Objective: Several single nucleotide polymorphisms associated with prostate cancer risk have been reported in recent years. We evaluated polymorphisms in the human glandular kallikrein 2 (KLK2) genes because the protein product of this gene is known to ...
Bailey, Tracey   +2 more
core   +1 more source

The First Case of a Class I Glucose-6-phosphate Dehydrogenase Deficiency, G6PD Santiago de Cuba (1339 GA), in a Chinese Population as Found in a Survey for G6PD Deficiency in Northeastern and Central China [PDF]

open access: yes, 2010
In Liaoning Province in northeastern China, we found a G6PD-deficient patient at the age of 3. By the classification of the World Health Organization, this patient was categorized as class I (very severe G6PD deficiency).
Hirai, Makoto   +5 more
core   +1 more source

Host candidate gene polymorphisms and clearance of drug-resistant parasites [PDF]

open access: yes, 2011
Resistance to anti-malarial drugs is a widespread problem for control programmes for this devastating disease. Molecular tests are available for many anti-malarial drugs and are useful tools for the surveillance of drug resistance.
Achidi, EA   +21 more
core   +3 more sources

Is personalized medicine achievable in obstetrics? [PDF]

open access: yes, 2014
Personalized medicine seeks to identify the right dose of the right drug for the right patient at the right time. Typically, individualization of therapy is based on the pharmacogenomic makeup of the individual and environmental factors that alter drug ...
Flockhart, David A.   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy